Celgene Corp (CELG.OQ)
18 Jan 2019
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2018||Chairman of the Board, Chief Executive Officer|
|2018||President - Global Clinical Development|
|45||2018||Chief Financial Officer, Executive Vice President|
|49||2017||President, Global Inflammation & Immunology Franchise|
|53||2016||President - Research and Early Development|
- Celgene, Bristol-Myers set $2.2 billion termination fee for their mega deal
- Celgene, Bristol-Myers set $2.2 bln termination fee for their mega deal
- BRIEF-Ribon Therapeutics Raises $65 Mln
- Bristol-Myers to buy Celgene for $74 billion in largest biopharma deal |
- UPDATE 7-Bristol-Myers to buy Celgene for $74 bln in largest biopharma deal